Previous 10 | Next 10 |
2023-09-28 11:07:29 ET More on BioMarin Pharmaceutical BioMarin: Q2 2023 Confirmed My Bullish View BioMarin: More Growth Is Coming BioMarin upgraded at BMO after FDA nod for hemophilia A therapy Seeking Alpha’s Quant Rating on BioMarin Pharmaceutical ...
- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit - Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years ...
2023-09-15 11:05:45 ET More on Lilly, Ascendis, and Novartis Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Sandoz to commercialize biosimilar to J&J blockbuster drug ...
COPENHAGEN, Denmark, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA ® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 1...
2023-09-14 13:51:53 ET More on Ascendis Seeking Alpha’s Quant Rating on Ascendis Pharma Historical earnings data for Ascendis Pharma Financial information for Ascendis Pharma Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Ascendis P...
- Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Europe...
2023-09-12 09:37:33 ET Summary Ascendis Pharma's Q2 2023 revenue jumped to $50.7M, driven mainly by Skytrofa sales, but net loss hit $129.9M. Liquidity concerns persist with an 11.4-month cash runway and sizable debt of $512.6M, impacting future financing options. Recommendati...
2023-09-05 19:43:02 ET Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 05, 2023, 04:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vic...
2023-09-05 16:23:31 ET More on Ascendis Pharma Seeking Alpha’s Quant Rating on Ascendis Pharma Historical earnings data for Ascendis Pharma Financial information for Ascendis Pharma Balancing Prospects And Perils: An Analysis Of Ascendis Pharma And Its...
• P roceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...